IL 4 DIRECTED IMMUNE RESPONSES TO CAEV SU
IL 4 对 CAEV SU 的定向免疫反应
基本信息
- 批准号:6168728
- 负责人:
- 金额:$ 7.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-07-01 至 2001-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
1. Research Proposal: The proposed research will utilize plasmid
expression vectors to initiate a Type 2 immune response to lentiviral
envelope proteins and determine if the induced Type 2 immune response
leads to the development of clinical disease following homologous virus
challenge. The long-term objective of this research is to identify
critical lymphocyte-mediated immune effector mechanisms that allow
lentiviral replication and initiation of clinical disease in outbred
species. The lentiviral system to be studied is caprine arthritis
encephalitis virus (CAEV) in goats. Goats become persistently infected
with CAEV and either remain asymptomatic or progress to clinical disease
characterized by arthritis. Symptomatic goats have intralesional memory
and immunoglobulin producing B-lymphocytes, increased serum and synovial
fluid titers of polyclonal IgG1 and CAEV SU reactive antibodies, and
increased CAEV SU responsive Th2 lymphocytes compared to asymptomatic
goats. These findings suggest that clinical disease in CAEV infected
goals may be determined by a dominant viral specific type 2 immune
response. The proposed specific aims permit investigation of the role
of Type 2 cytokines, specifically IL-4, in the initial segregation of
the immune response to a Type 2 profile and the progression of disease
from lentiviral infections. In specific aim 1, immunization with a
mammalian expression vector that encodes CAEV SU in conjunction with a
second expression vector encoding IL-4 will be used to stimulate antigen
specific T helper lymphocytes and initiate a Type 2 immune response.
Documented studies in mice have shown that intramuscular injection of
expression vectors that encode IL-4 stimulate the development of Type
2 immune responses to co-immunized viral antigens. In specific aim 2,
the immunized goats will be infected with CAEV and disease progression
evaluated. Anticipated results will demonstrate the use of recombinant
cytokines to focus antigen specific T helper lymphocytes pathways in
outbred species and provide an opportunity to directly examine the role
of Type 2 responses in a persistent lentivirus infection. 2. Candidate:
The candidate is a veterinarian completing a residency in comparative
pathology and is a Ph.D candidate. In preparation for research, the
candidate has completed graduate courses in biochemistry, molecular
biology, mechanism of disease, and immunopathology. This proposal
constitutes his doctoral research and will provide an excellent basis
for future independent research in lentivirus infections.
1. 研究计划:拟利用质粒进行研究
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kevin Roy Snekvik其他文献
Kevin Roy Snekvik的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kevin Roy Snekvik', 18)}}的其他基金
FDA Veterinary Laboratory Investigation and Response Network Cooperative Agreement Program-WA
FDA 兽医实验室调查和响应网络合作协议计划-西澳
- 批准号:
10631177 - 财政年份:2012
- 资助金额:
$ 7.65万 - 项目类别:
FDA Veterinary Laboratory Investigation and Response Network Cooperative Agreement Program-WA
FDA 兽医实验室调查和响应网络合作协议计划-西澳
- 批准号:
10570676 - 财政年份:2012
- 资助金额:
$ 7.65万 - 项目类别:
IL 4 DIRECTED IMMUNE RESPONSES TO CAEV SU
IL 4 对 CAEV SU 的定向免疫反应
- 批准号:
2680489 - 财政年份:1998
- 资助金额:
$ 7.65万 - 项目类别:
IL 4 DIRECTED IMMUNE RESPONSES TO CAEV SU
IL 4 对 CAEV SU 的定向免疫反应
- 批准号:
2886118 - 财政年份:1998
- 资助金额:
$ 7.65万 - 项目类别:
相似国自然基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
- 批准号:31171277
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
- 批准号:31070748
- 批准年份:2010
- 资助金额:34.0 万元
- 项目类别:面上项目
相似海外基金
Tissue tropism of PD-1 therapy in ulcerative colitis and rheumatoid arthritis
PD-1治疗溃疡性结肠炎和类风湿性关节炎的组织向性
- 批准号:
MR/Y009681/1 - 财政年份:2024
- 资助金额:
$ 7.65万 - 项目类别:
Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
- 批准号:
MR/Y022947/1 - 财政年份:2024
- 资助金额:
$ 7.65万 - 项目类别:
Research Grant
Preclinical development of an extracellular vesicle biotherapeutic for juvenile idiopathic arthritis
幼年特发性关节炎细胞外囊泡生物治疗药物的临床前开发
- 批准号:
10068495 - 财政年份:2024
- 资助金额:
$ 7.65万 - 项目类别:
Collaborative R&D
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
- 批准号:
24K19237 - 财政年份:2024
- 资助金额:
$ 7.65万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Exploring the inflammatory mediators degraded by MMP-2 in MMP-2-deficient mice with knee arthritis through a novel TMT-TAILS quantitative proteomics
通过新型 TMT-TAILS 定量蛋白质组学探索 MMP-2 缺陷型膝关节炎小鼠中 MMP-2 降解的炎症介质
- 批准号:
24K19850 - 财政年份:2024
- 资助金额:
$ 7.65万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of an adaptive platform trial to prevent Rheumatoid Arthritis in partnership with First Nations People.
与原住民合作开发预防类风湿关节炎的适应性平台试验。
- 批准号:
491810 - 财政年份:2023
- 资助金额:
$ 7.65万 - 项目类别:
Operating Grants
The role of diet, as mediated by the gut microbiome, on childhood arthritis disease activity: a feasibility intervention study.
肠道微生物组介导的饮食对儿童关节炎疾病活动的作用:一项可行性干预研究。
- 批准号:
489316 - 财政年份:2023
- 资助金额:
$ 7.65万 - 项目类别:
Operating Grants
Investigation of hypoxia-inducible factor-1 (HIF-1) as a novel therapeutic target for juvenile idiopathic arthritis.
研究缺氧诱导因子-1 (HIF-1) 作为幼年特发性关节炎的新治疗靶点。
- 批准号:
23K14987 - 财政年份:2023
- 资助金额:
$ 7.65万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
DEMORA: DEep spatial characterization of synovial MacrOphages in Rheumatoid Arthritis
DEMORA:类风湿性关节炎滑膜巨噬细胞的深度空间特征
- 批准号:
EP/Y027760/1 - 财政年份:2023
- 资助金额:
$ 7.65万 - 项目类别:
Fellowship
The roles and mechanisms of inflammation resolution in the development of Rheumatoid Arthritis
炎症消退在类风湿关节炎发展中的作用和机制
- 批准号:
10733789 - 财政年份:2023
- 资助金额:
$ 7.65万 - 项目类别:














{{item.name}}会员




